Cargando…

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019

To determine the impact of tocilizumab, a monoclonal antibody against the interleukin 6 receptor, on survival in patients with coronavirus disease 2019. DESIGN: Observational cohort study of patients hospitalized with coronavirus disease 2019 between March 1, 2020, and April 24, 2020. A propensity-m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Tyler C., Adhikari, Samrachana, Tatapudi, Vasishta, Holub, Meredith, Kunichoff, Dennis, Troxel, Andrea B., Montgomery, Robert A., Sterman, Daniel H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671881/ https://www.ncbi.nlm.nih.gov/pubmed/33225307 http://dx.doi.org/10.1097/CCE.0000000000000283

Ejemplares similares

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Assessment of Community-Level Disparities in Coronavirus Disease 2019 (COVID-19) Infections and Deaths in Large US Metropolitan Areas
por: Adhikari, Samrachana, et al.
Publicado: (2020)

Pharmacologic Complement Inhibition in Clinical Transplantation
por: Tatapudi, Vasishta S., et al.
Publicado: (2017)

Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads
por: Tatapudi, Vasishta S., et al.
Publicado: (2019)

Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
por: Alattar, Rand A., et al.
Publicado: (2022)

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
por: Tatapudi, Vasishta S., et al.
Publicado: (2018)

508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study
por: Alattar, Rand A, et al.
Publicado: (2021)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023)

Early Intubation and Increased Coronavirus Disease 2019 Mortality: A Propensity Score–Matched Retrospective Cohort Study
por: Parish, Austin J., et al.
Publicado: (2021)

Hospitalization and survival of solid organ transplant recipients with coronavirus disease 2019: A propensity matched cohort study
por: Swan, Joshua T., et al.
Publicado: (2022)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Symptomatic Central Venous Stenosis in a Hemodialysis Patient Leading to Loss of Arteriovenous Access: A Case Report and Literature Review
por: Tatapudi, Vasishta S., et al.
Publicado: (2014)

Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study
por: Liang, Meng-yuan, et al.
Publicado: (2021)

Impact of Dementia on Mortality Due to Coronavirus Disease 2019: Propensity-Score-Matching Study
por: Jeon, Jin Pyeong, et al.
Publicado: (2022)

Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
por: Tanimoto, Takuya, et al.
Publicado: (2022)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study
por: Kuwahara, Masaatsu, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
por: Rodríguez-Molinero, Alejandro, et al.
Publicado: (2021)

Overweight and Obesity are Risk Factors for Coronavirus Disease 2019: A Propensity Score-Matched Case-Control Study
por: Ji, Wonjun, et al.
Publicado: (2021)

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
por: Morrison, Austin R., et al.
Publicado: (2020)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

The effect of outpatient antibiotic treatment of coronavirus disease 2019 on the outcomes in the emergency department: a propensity score matching study
por: Atić, Armin, et al.
Publicado: (2022)

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
por: Sirimaturos, Michael, et al.
Publicado: (2020)

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
por: Chen, Chong-xiang, et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
por: Sinha, Pranay, et al.
Publicado: (2021)

Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study
por: Kamran, Sultan Mehmood, et al.
Publicado: (2021)

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
por: Abdullah, Shazia, et al.
Publicado: (2021)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series
por: Abe, Takashi, et al.
Publicado: (2022)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor
por: Karpel, H. Charli, et al.
Publicado: (2020)

Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force
por: Tanaka, Hiromu, et al.
Publicado: (2023)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ufkjqtgl8ueiicckb6b3k41ct5